tradingkey.logo

Aptose Reports Tuspetinib Improves Standard Of Care Treatment Across Diverse Populations Of Diagnosed AML In Trial

ReutersAug 18, 2025 2:15 PM

- Aptose Biosciences Inc APS.TO:

  • APTOSE REPORTS EARLY DATA DEMONSTRATING TUSPETINIB IMPROVES STANDARD OF CARE TREATMENT ACROSS DIVERSE POPULATIONS OF NEWLY DIAGNOSED AML IN PHASE 1/2 TUSCANY TRIAL

  • APTOSE BIOSCIENCES INC - TUS ADDED TO VEN+AZA SHOWS 100% CR/CRH AT 80 MG AND 120 MG

  • APTOSE BIOSCIENCES INC - TUS ADDED TO VEN+AZA IMPROVES MRD-NEGATIVITY TO 78% AMONG RESPONDERS

  • APTOSE BIOSCIENCES INC - BROAD SPECTRUM ACTIVITY AND SAFETY AT 120 MG DOSE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI